Loading...
OTCM
TLOG
Market cap0kUSD
Feb 26, Last price  
0.00USD
Name

TetraLogic Pharmaceuticals Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
0k
-18,926,409-16,272,803-22,717,818-39,318,368-56,108,3390000
CFO
0k
-17,332,518-15,927,558-12,768,951-32,366,174-34,889,3950000

Profile

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
IPO date
Dec 12, 2013
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2022‑122021‑122020‑122019‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
0.00
-98.00%
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT